Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) has launched MINNEBRO (esaxerenone) tablets as a treatment for patients with hypertension in Japan.
Pfizer has announced the opening of a new 175,000 square-foot manufacturing facility in Andover, Massachusetts.
Novartis has agreed to acquire dry eye drug Xiidra (lifitegrast ophthalmic solution) 5% from Takeda for $3.4bn.
Teva Pharmaceuticals USA has initiated a voluntary recall in the US, to the patient level, of 35 lots of bulk Losartan Potassium USP Tablets (6 lots of 25 mg strength and 29 lots of 100 mg strength).
Kite, a Gilead Company (Nasdaq: GILD), today announced plans for a new facility in Frederick County, Maryland, which will produce innovative cell therapies for people with cancer.
British drugmaker GlaxoSmithKline (GSK) is set to invest $100m to expand long-term vaccine manufacturing capabilities at its Hamilton facility in Montana, US.
Eli Lilly and Company (NYSE: LLY) today announced that it has entered into an agreement to sell the rights in China for two legacy Lilly antibiotic medicines, Ceclor and Vancocin, as well as a manufacturing facility in Suzhou, China that produces Ceclor, to Eddingpharm, a China-based specialty pharmaceutical company.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of a generic version of VESIcare (solifenacin succinate) Tablets, 5 mg and 10 mg, in the U.S.
Jordan-based MS Pharma has agreed to acquire European pharmaceutical firm, Genepharm, for an undisclosed sum.
Sun Pharmaceutical Industries Ltd. announced that INFUGEM (gemcitabine in sodium chloride injection), for intravenous use, is now commercially available in the U.S.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.